Skip to content

Study · Case report or series · n = 1 · 2026

2 results

Non-Arteritic Anterior Ischaemic Optic Neuropathy Associated with Semaglutide use.

Kearney M, Smyth NM, Hassan HSA, Khan MS

Irish medical journal28 Sept 2026

PMID42808150 (opens in a new tab)PepBankPUB-42808150
Publisher pageAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In a woman in her 70s with vascular risk factors, non-arteritic ischaemic optic neuropathy occurred after six months of semaglutide use.

    In plain wordsA woman in her 70s developed an optic nerve problem after six months on semaglutide. The report does not prove semaglutide caused it.

    Peptide
    Semaglutide
    Outcome
    Not applicableNon-arteritic anterior ischaemic optic neuropathy
    Study

    n = 1

    Outcome group
    Adverse events · Eye
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Formal ophthalmological assessment demonstrated superior optic disc swelling with an inferior visual field defect, consistent with NAION.TreatmentThe patient had been taking semaglutide, as prescribed, for the six months prior to presentation.
    1 context sentence
    Summary · context
    This case discusses a woman in her 70s with vascular risk factors who presented with a three-day history of progressive left sided visual disturbance.
  2. 02HumanCase report or seriesSafety outcome

    In the same patient, visual acuity partially improved after semaglutide was stopped.

    In plain wordsIn this one patient, vision partly improved after semaglutide was stopped.

    Peptide
    Semaglutide
    Outcome
    IncreaseVisual acuity after stopping semaglutide
    Study

    n = 1

    Outcome group
    Adverse events · Eye
    Studied dose
    Dose not stated

    Source sentences

    Summary
    This was identified as a potential contributory agent and was discontinued. Visual acuity partially improved following cessation of semaglutide.
    1 context sentence
    Summary · context
    This case discusses a woman in her 70s with vascular risk factors who presented with a three-day history of progressive left sided visual disturbance.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.